Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

IVA

Inventiva (IVA)

Inventiva
Date:
Sort by:
 Showing the most relevant articles for your search:EU:IVA
DateTimeSourceHeadlineSymbolCompany
02/14/20224:00PMGlobeNewswire Inc.Inventiva publie sa position de trésorerie et son chiffre d’affaires pour l’exercice 2021EU:IVAInventiva
01/31/20224:00PMGlobeNewswire Inc.Inventiva reçoit un paiement d'étape de 4 M€ de la part d’AbbVie suite au lancement de l’étude de Phase IIb avec cedirogantEU:IVAInventiva
01/31/20224:00PMGlobeNewswire Inc.Inventiva receives a €4 million milestone payment from AbbVie for cedirogant Phase IIb initiationEU:IVAInventiva
01/31/20224:00PMGlobeNewswire Inc.Inventiva receives a €4 million milestone payment from AbbVie for cedirogant Phase IIb initiationEU:IVAInventiva
01/20/20224:00PMGlobeNewswire Inc.Inventiva announces participation at several conferences in January and February 2022EU:IVAInventiva
01/20/20224:00PMGlobeNewswire Inc.Inventiva annonce sa participation à plusieurs conférences investisseurs en janvier et février 2022EU:IVAInventiva
01/20/20224:00PMGlobeNewswire Inc.Inventiva announces participation at several conferences in January and February 2022EU:IVAInventiva
01/14/20222:00AMGlobeNewswire Inc.Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler CheuvreuxEU:IVAInventiva
01/14/20222:00AMGlobeNewswire Inc.Half-Year Review of Inventiva’s Liquidity Contract with Kepler CheuvreuxEU:IVAInventiva
12/16/20214:00PMGlobeNewswire Inc.Inventiva to present at the 40th Annual J.P. Morgan Healthcare ConferenceEU:IVAInventiva
12/16/20214:00PMGlobeNewswire Inc.Inventiva annonce sa participation à la « 40th Annual J.P. Morgan Healthcare Conference »EU:IVAInventiva
12/16/20214:00PMGlobeNewswire Inc.Inventiva to present at the 40th Annual J.P. Morgan Healthcare ConferenceEU:IVAInventiva
12/06/20214:00PMGlobeNewswire Inc.Inventiva announces positive results of clinical thorough QT study conducted with lanifibranorEU:IVAInventiva
12/06/20214:00PMGlobeNewswire Inc.Inventiva announces positive results of clinical thorough QT study conducted with lanifibranorEU:IVAInventiva
12/06/20214:00PMGlobeNewswire Inc.Inventiva annonce les résultats positifs de l’étude clinique « thorough » QT menée avec lanifibranorEU:IVAInventiva
11/10/20214:00PMGlobeNewswire Inc.Inventiva reports 2021 Third Quarter Financial InformationEU:IVAInventiva
11/10/20214:00PMGlobeNewswire Inc.Inventiva publie ses informations financières du 3ème trimestre 2021EU:IVAInventiva
11/10/20214:00PMGlobeNewswire Inc.Inventiva reports 2021 Third Quarter Financial InformationEU:IVAInventiva
11/03/20214:00PMGlobeNewswire Inc.Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021  EU:IVAInventiva
11/03/20214:00PMGlobeNewswire Inc.Inventiva organise un webcast avec des leaders d’opinion à l’occasion du congrès The Liver Meeting™ 2021 de l’AASLDEU:IVAInventiva
11/03/20214:00PMGlobeNewswire Inc.Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021  EU:IVAInventiva
10/29/20219:29AMGlobeNewswire Inc.Inventiva announces participation at several conferences in November 2021EU:IVAInventiva
10/29/20219:29AMGlobeNewswire Inc.Inventiva announces participation at several conferences in November 2021EU:IVAInventiva
10/29/20219:29AMGlobeNewswire Inc.Inventiva annonce sa participation à plusieurs conférences investisseurs en novembre 2021EU:IVAInventiva
10/27/20214:00PMGlobeNewswire Inc.Inventiva annonce le design de LEGEND, un essai clinique de Phase IIa combinant lanifibranor et empagliflozine, un inhibiteur du SGLT2, chez des patients atteints de la NASH et de diabète de type 2EU:IVAInventiva
10/27/20214:00PMGlobeNewswire Inc.Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetesEU:IVAInventiva
10/27/20214:00PMGlobeNewswire Inc.Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetesEU:IVAInventiva
10/20/20215:07PMGlobeNewswire Inc.« The New England Journal of Medicine » publie les résultats de l’étude clinique de Phase IIb NATIVE d’Inventiva avec lanifibranor dans la NASHEU:IVAInventiva
10/20/20215:07PMGlobeNewswire Inc.The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASHEU:IVAInventiva
10/20/20215:07PMGlobeNewswire Inc.The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASHEU:IVAInventiva
 Showing the most relevant articles for your search:EU:IVA